Trametinib
Brain Cancer Awareness Month: Vaccine confers benefit, AI identifies potential targets
May is Brain Cancer Awareness Month.
FDA approves first systemic therapy for children with BRAF V600E-mutated low-grade glioma
The FDA approved dabrafenib with trametinib for children with previously untreated low-grade glioma who harbor BRAF V600E mutations and require systemic therapy.
VIDEO: Emergence of targeted therapies ‘broadened treatment options’ for cholangiocarcinoma
In this video, Sumera I. Ilyas, MBBS, gastroenterologist, physician-scientist and transplant hepatologist with Mayo Clinic, discusses the current landscape of targeted treatment in cholangiocarcinoma.
Immunotherapy added to BRAF/MEK inhibitor improves OS for anaplastic thyroid cancer
FDA approves Tafinlar-Mekinist combination for BRAF V600E-mutated solid tumors
The FDA granted accelerated approval to dabrafenib plus trametinib for treatment of certain patients with unresectable or metastatic solid tumors that harbor BRAF V600E mutations.
Targeted therapy provides ‘phenomenal’ benefit for certain children with glioma
CHICAGO — A combination of two targeted therapies significantly improved outcomes compared with standard care for children with BRAF V600 mutation-positive low-grade glioma, according to study results presented at ASCO Annual Meeting.
Trametinib new standard-of-care option for recurrent low-grade serous ovarian cancer
Trametinib should be a new standard of care for women with recurrent low-grade serous carcinoma, according to study published in The Lancet that showed a 52% reduction in risk for disease progression or death vs. current treatment options.
Immunotherapy before targeted therapy extends OS in metastatic melanoma
Patients with BRAF V600 mutation-positive metastatic melanoma who received an immune checkpoint inhibitor combination followed by targeted therapy survived longer than those who received the reverse sequence, according to study findings.
VIDEO: Exciting movement happening in KRAS-mutated lung cancer treatments
In this video, Pasi Jänne, MD, PhD, professor of medicine, Harvard Medical School, discussed studies looking at combining therapies with sotorasib. Those combinations included sotorasib and trametinib for KRAS p.G12C-mutated solid tumors and sotorasib and afatinib for KRAS p.G12C mutated non-small cell lung cancer.